Monoclonal antibodies (mAbs) directed against IgE (omalizumab) or cytokines such as IL-5 (mepolizumab and reslizumab), and IL-4/IL-13 (dupilumab) have been tested as innovative therapeutic approaches of CRSwNP. This evidence concerns the gene IL13 and chronic rhinosinusitis with nasal polyps.